Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Positive|Male Breast Carcinoma|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: OTHER: Laboratory Biomarker Analysis|DRUG: Lapatinib Ditosylate|DRUG: Tamoxifen Citrate
Sponsor: National Cancer Institute (NCI)